MABPHARM-B (02181) released its interim results, with shareholders' profit attributable amounting to 31.36 million yuan, a year-on-year increase of 982.1%.

22:28 28/08/2026

Maibo Pharmaceutical-B (02181) announced its interim results for the six months ending June 30, 2026, with the group's operating income reaching RMB 398 million, a year-on-year increase of 45.1%; the profit attributable to shareholders was RMB 31.36 million, a significant year-on-year increase of 982.1%; earnings per share were RMB 0.01.

MABPHARM-B (02181) released its interim results for the six months ending June 30, 2026, with the group reporting revenue of RMB 398 million, a year-on-year increase of 45.1%; shareholders' profit attributable to the company was RMB 31.36 million, a year-on-year increase of 982.1%; earnings per share were RMB 0.01.

TONGSHIFU (00664) released its interim performance report, with a net profit of 1.281 million yuan, a decrease of 95.8% year-on-year.

JIAYUAN SER (01153) released its interim results, with a profit attributable to shareholders of 14.883 million yuan, a year-on-year decrease of 89.37%.

MTT GROUP (02350) plans to acquire 100% equity of Qingzhan International Artificial Intelligence Co., Ltd. for HKD 20 million, deepening its business layout in the AI field.

TONGSHIFU (00664) released its interim performance report, with a net profit of 1.281 million yuan, a decrease of 95.8% year-on-year.

JIAYUAN SER (01153) released its interim results, with a profit attributable to shareholders of 14.883 million yuan, a year-on-year decrease of 89.37%.

MTT GROUP (02350) plans to acquire 100% equity of Qingzhan International Artificial Intelligence Co., Ltd. for HKD 20 million, deepening its business layout in the AI field.